Introducing The Journal: Trillion Dollar Shot
Science Vs
The Journey of Developing Ozempic: Overcoming Challenges in GLP-1 Research
Explore the early stages of developing a new class of drugs based on GLP-1 hormone to treat diabetes, as recounted by lead researcher Lada Knudsen and her team at Novo Nordisk. Despite facing skepticism, resource limitations, and safety concerns during clinical trials, the team's perseverance and dedication eventually led to the successful development and approval of Ozempic after more than a decade of hard work.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
